Compugen Ltd. Stock
Compugen Ltd. Stock
Compugen Ltd. gained 1.380% today.
The community is currently still undecided about Compugen Ltd. with 1 Buy predictions and 0 Sell predictions.
With a target price of 3 € there is potential for a 127.96% increase which would mean more than doubling the current price of 1.32 € for Compugen Ltd..
Pros and Cons of Compugen Ltd. in the next few years
Pros
?
M***** P*******
?
G***** c******* t* c**********
?
C******** o* t** e**********
Cons
?
B****
?
S********** s********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Compugen Ltd. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Compugen Ltd. | 1.380% | 1.858% | -4.638% | -9.366% | -12.963% | 67.643% | - |
| Intellia Therapeutics Inc | -3.540% | 1.039% | 8.485% | -31.402% | -29.802% | -75.388% | -84.658% |
| Arbutus Biopharma Corp. | -1.450% | 4.910% | 6.484% | 29.784% | 31.328% | 77.569% | 19.519% |
| Krystal Biotech | 0.850% | 4.672% | 13.930% | 39.043% | 41.327% | 190.676% | - |
Comments
Compugen Ltd. (NASDAQ: CGEN) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $4.00 price target on the stock.
Show more
Ratings data for CGEN provided by MarketBeat
Compugen Ltd. (NASDAQ: CGEN) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Show more
Ratings data for CGEN provided by MarketBeat
Compugen Ltd. (NASDAQ: CGEN) had its price target lowered by analysts at Truist Financial Co. from $5.00 to $4.00. They now have a "buy" rating on the stock.
Show more
Ratings data for CGEN provided by MarketBeat
